Home › Funds › Fairmount Funds Management LLC › CBIO
Fairmount Funds Management LLC position in CBIO
CRESCENT BIOPHARMA INC. · Health Care
Fairmount Funds Management LLC reported holding 2,747,866 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q2 2026 13F filing — a position valued at US$49.5M, representing 3.27% of its reported portfolio and ranking #9 among its reported holdings. Fairmount Funds Management LLC has disclosed CBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Fairmount Funds Management LLC's CBIO position evolved
Fairmount Funds Management LLC first disclosed a stake in CBIO in Q2 2025 at 1,387,866 shares (US$22.4M). The position peaked in Q1 2026 at 2,747,866 shares, worth US$50.5M. Across 5 filings, Fairmount Funds Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,747,866 shares valued at US$49.5M. Notable position changes include a 98% increase in Q4 2025 (shares rose 55% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.39M | $22.40M | New |
| Q3 2025 | 1.39M | $16.50M | Hold |
| Q4 2025 | 2.75M | $32.59M | Add |
| Q1 2026 | 2.75M | $50.48M | Hold |
| Q2 2026 | 2.75M | $49.46M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CBIO and 13F data
CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 71 other funds we track also report a position in CBIO — the largest reported positions include BVF INC/IL (US$49.5M), Venrock Adviser, LLC (US$38.4M), Logos Global Management LP (US$34.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CBIO
- BVF INC/IL 2.75M sh · $49.48M · Q2 2026
- Venrock Adviser, LLC 2.13M sh · $38.40M · Q2 2026
- Logos Global Management LP 1.90M sh · $34.20M · Q2 2026
- FCPM III SERVICES B.V. 1.68M sh · $30.20M · Q2 2026
- Vestal Point Capital, LP 1.63M sh · $29.34M · Q2 2026
- Opaleye Management Inc. 1.32M sh · $23.75M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.16M sh · $20.88M · Q2 2026
- Boxer Capital Management, LLC 453.69K sh · $8.17M · Q2 2026
- NEXTBio Capital Management LP 372.86K sh · $6.71M · Q2 2026
- Remedium Capital Partners, LLC 361.25K sh · $6.50M · Q2 2026
- STEMPOINT CAPITAL LP 182.38K sh · $3.28M · Q2 2026
- Exome Asset Management LLC 127.77K sh · $2.30M · Q2 2026
More on Fairmount Funds Management LLC
FAQ
How long has Fairmount Funds Management LLC held CBIO?
Fairmount Funds Management LLC has disclosed CBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Fairmount Funds Management LLC's current position in CBIO?
As of Q2 2026, Fairmount Funds Management LLC holds 2.75M shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $49.46M, representing 3.27% of its reported portfolio and ranking #9.
Has Fairmount Funds Management LLC been buying or selling CBIO?
In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in CBIO. The position peaked in Q1 2026 at 2.75M shares.
Which other funds hold CBIO?
Other major institutional holders of CBIO include BVF INC/IL, Venrock Adviser, LLC, Logos Global Management LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.